首页> 外文期刊>Australian and New Zealand Journal of Obstetrics and Gynecology >A randomized clinical trial comparing oral misoprostol with synthetic oxytocin or syntometrine in the third stage of labour.
【24h】

A randomized clinical trial comparing oral misoprostol with synthetic oxytocin or syntometrine in the third stage of labour.

机译:在第三产程中比较口服米索前列醇与合成催产素或间苯二甲酮的随机临床试验。

获取原文
获取原文并翻译 | 示例
           

摘要

This is a multicentre, blocked, randomized trial to compare the efficacy of oral misoprostol 400 microg with current injectable uterotonic agents (oxytocin/ Syntometrine) used prophylactically in the third stage of labour. Main outcome measures were blood loss, use of a second uterotonic agent and difference in haemoglobin level from antepartum to postpartum. Data analysis from 863 women showed a statistically significant increase in both the mean blood loss (p < 0.001) and the rate of postpartum haemorrhage > 500 mL, (RR 2.72: 95% C1 1.73-4.27) in the misoprostol group compared to the oxytocin/Syntometrine group. The use of a second uterotonic agent was higher in the misoprostol group (RR 2.89: 95% Cl 2.00-4.18) as well as a greater decrease in postpartum haemoglobin (p = 0.015). Oral misoprostol 400 microg is significantly less effective than the traditional intramuscular uterotonic agents currently used and therefore cannot be considered as a viable option to these agents in the management of the third stage of labour.
机译:这是一项多中心,封闭,随机试验,比较了口服米索前列醇400微克与当前在第三产程中预防性使用的宫缩剂(催产素/ Syntometrine)的疗效。主要的预后指标是失血,使用第二种宫缩剂和产前至产后血红蛋白水平的差异。来自863名女性的数据分析显示,与催产素相比,米索前列醇组的平均失血(p <0.001)和产后出血率> 500 mL均有统计学上的显着增加(RR 2.72:95%C1 1.73-4.27) / Syntometrine组。米索前列醇组使用第二种宫缩剂的比例更高(RR 2.89:95%Cl 2.00-4.18),并且产后血红蛋白的降低更大(p = 0.015)。口服米索前列醇400微克的疗效远不如目前使用的传统肌内子宫收缩剂,因此不能认为这些药物在分娩第三阶段时是可行的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号